Results 301 to 310 of about 11,116,898 (377)

The power of ESG in shaping dividend policy: Illuminating the role of financial sustainability in an emerging market. [PDF]

PLoS One
Almulhim AA, Aljughaiman AA, Al Barrak T, Chebbi K, Amin N.   +4 more
europepmc   +1 more source

Employees Financial Participation in France : paying workers to increase shareholder value creation

, 2009
Wilfried Pennetier
openalex   +1 more source

Power, choice, exposure and fragility: Reframing fairness in equity for the corporate and insolvency sphere

International Insolvency Review, EarlyView.
Abstract Where is the place of humanity in current corporate and insolvency frameworks and their theoretical underpinning? How can it be assured that the institutions that have been invented through human ingenuity and brilliance serves the collective human experience fully and equitably? Insolvency law has long been theoretically conceptualised on the
Jennifer L. L. Gant
wiley   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Centralized allocation of decision rights and enterprise transformation and upgrading: Based on human capital level and capital allocation efficiency. [PDF]

PLoS One
Tang Q, Sun H.
europepmc   +1 more source

Inhibition of autotaxin activity with IOA‐289 decreases fibrosis in mouse E0771 breast tumors

International Journal of Cancer, Volume 157, Issue 6, Page 1205-1217, 15 September 2025.
What's new? Lysophosphatidate is one of the critical mediators of fibrosis formation in the tumor microenvironment, which hinders immune surveillance and therapy. Building on their previous finding that blocking lysophosphatidate production with the autotaxin inhibitor, IOA‐289 decreased tumor growth by approximately 60%, here the authors show that ...
Xiaoyun Tang, Humayara Khan, Karolina Niewola‐Staszkowska, Frank Wuest, David N. Brindley   +4 more
wiley   +1 more source

ASO Author Reflections: Nevus-Associated Melanoma: A Prognostically Distinct Entity. [PDF]

Ann Surg Oncol
Riaz N, Olofsson Bagge R.
europepmc   +1 more source

Shareholder Value - nur ein Schlagwort? [PDF]

, 2010
Härtel, Hans-Hagen
core  

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing

International Journal of Cancer, EarlyView.
What's New? Fluoropyrimidines, a key component of chemotherapy regimens for a variety of solid tumors, can cause severe toxicity. Patients who have specific genetic variants in the DPYD gene, which encodes an enzyme that inactivates fluoropyrimidines, have increased susceptibility to this toxicity.
Sofía L. J. Peeters, Didier Meulendijks, Zerina Kadric, Sara Ibrovic, Geert‐Jan Creemers, Vanja Milosevic, Matthijs van de Poll, Lieke H. J. Simkens, Birgit A. L. M. Deiman, Hans Gelderblom, Henk‐Jan Guchelaar, Anna M. J. Thijs, Maarten J. Deenen   +12 more
wiley   +1 more source

Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. [PDF]

BMC Cancer
Boegemann M, Bennamoun M, Dourthe LM, Encarnacion JA, Hegele A, Hellmis E, Latorzeff I, Leicht W, Oñate-Celdrán J, Rosino-Sánchez A, Hanna K, Lencart J, Lukac M, Schioppa CA, Van Sanden S, Kramer G.   +15 more
europepmc   +1 more source